Schaeffer's 43rd Anniversary Stock Picks in 2024

Penny Stock at Bottom of Nasdaq After Drug Data

CLSD's eye therapy drug failed a late-stage study

Managing Editor
Nov 5, 2018 at 9:55 AM
facebook X logo linkedin


The shares of Clearside Biomedical Inc (NASDAQ:CLSD) are down a whopping 52.7% to trade at $2.63 this morning, after Xipere, the company's eye therapy drug, failed a late-stage study. The drugmaker will discontinue the development of the combination therapy for retinal vein blockage, but will still file a marketing application for Xipere at year's end for treating uveitic macular edema. 

Out of the gate, CLSD fell to $2.49, a new record low. The shares have been carving out a channel of lower lows since mid-July, with their 30-day moving average containing any breakouts. Even prior to today's drop, the equity had shed 20% this year, and is on its way to a fifth straight losing month. 

Analysts have been undeterred by the drug stock's recent struggles. Currently, all five of the brokerages covering CLSD rate it a "strong buy," and its consensus 12-month price target sits all the way up at $23. For reference, the security hasn't traded near that level in almost two years. 

Short sellers have been piling on, though. Short interest increased by nearly 20% in the last two reporting periods to 1.05 million shares, the most since August 15. However, this only represents 3.5% of CLSD's total available float, indicating there is still ample room aboard the bearish bandwagon. Of course, the shares are on the short-sale restricted list today.

 

A.I.’s Dirty Little Secret: The Real Power Behind The AI. Boom ✨

Anyone who’s seen the The Matrix movies knows that A.I. needs power.  Lots and lots of power.

If you’ve seen the movie, you also know the grizzly results of the ensuing battle for that power.

Now, Wall Street’s battle for A.I. power won’t go to such extremes. Hopefully?

A.I. needs more power and that means more opportunities for stock traders in the know.

Download your free copy of “The A.I. Revolution: 4 Stocks to Buy Now”!